Drug intelligence / Profile preview

BNH 103

Development stage: Preclinical
Lead developer: BnH Research
Modality: Small Molecules

Overview

BNH 103 is a preclinical-stage therapeutic candidate being developed by BnH Research for the treatment of autism. The drug is part of a pipeline focused on "plasticity-based therapeutics," which aims to address neurodevelopmental and neuropsychiatric disorders by reopening critical periods of cortical or synaptic plasticity. While specific molecular targets for BNH 103 have not been publicly disclosed, the program is designed to facilitate the reorganization and repair of neural circuits that are dysfunctional in individuals with autism spectrum disorders.

Beyond the preview

Go deeper on BNH 103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BNH 103.

Explore the full profile